Management of dyspnea at the end of life

Dyspnea: Mechanisms, Measurement and Management

Volumn , Issue , 2005, Pages 429-461

  Dudgeon, D ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057676378     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (149)

1. Lynn J. Serving patients who may die soon and their families. The role of hospice and other services. JAMA 2001; 285: 925-932.
2. Dudgeon DJ, Kristjanson L, Sloan JA, Lertzman M, Clement K. Dyspnea in cancer patients: prevalence and associated factors. J Pain Symptom Manage 2001; 21: 95-102.
3. Reuben DB, Mor V. Dyspnea in terminally ill cancer patients. Chest 1986; 89: 234-236.
4. Fainsinger R, MacEachern T, Hanson J, Miller MJ, Bruera E. Symptom control during the last week of life on a palliative care unit. J Palliat Care 1991; 7: 5-11.
5. Twycross RG, Lack SA. Respiratory symptoms. In: Twycross RG, Lack SA, eds. Therapeutics in Terminal Cancer. 2nd ed. London: Churchill Livingston, 1990: 123-136.
6. Curtis EB, Krech R, Walsh TD. Common symptoms in patients with advanced cancer. J Palliat Care 1991; 7: 25-29.
7. Heyse-Moore LH, Ross V, Mullee MA. How much of a problem is dyspnoea in advanced cancer? Palliat Med 1991; 5: 20-26.
8. Heyse-Moore LH. On Dyspnoea in Advanced Cancer [dissertation]. Southhampton, UK: Southampton University, 1993.
9. Muers MF, Round CE. Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organisation thoracic group. Thorax 1993; 48: 339-343.
10. Skilbeck J, Mott L, Page H, Smith D, Hjelmeland-Ahmedzai S, Clark D. Palliative care in chronic obstructive airways disease: a needs assessment. Palliat Med 1998; 12: 245-254.
11. McCarthy M, Lay M, Addington-Hall J. Dying from heart disease. J R Coll Phys Lond 1996; 30: 325-328.
12. Addington-Hall J, Lay M, Altmann D, McCarthy M. Symptom control, communication with health professionals, and hospital care of stroke patients in the last year of life as reported by surviving family, friends and officials. Stroke 1995; 26: 2242-2248.
13. Voltz R, Borasio GD. Palliative therapy in the terminal stage of neurological disease. J Neurol 1997; 244(suppl 4): S2-S10.
14. Brown ML, Carrieri V, Janson-Bjerklie S, Dodd MJ. Lung cancer and dyspnea: the patient’s perception. Oncol Nurs Forum 1986; 13: 19-24.
15. Roberts DK, Thorne SE, Pearson C. The experience of dyspnea in late-stage cancer. Patients’ and nurses’ perspectives. Cancer Nurs 1993; 16: 310-320.
16. McSweeny AJ, Grant I, Heaton RK, Adams KM, Timms RM. Life quality of patients with chronic obstructive pulmonary disease. Arch Intern Med 1982; 142: 473-478.
17. Gore JM, Brophy CJ, Greenstone MA. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax 2000; 55: 1000-1006.
18. O’Driscoll M, Corner J, Bailey C. The experience of breathlessness in lung cancer. Eur J Cancer Care 1999; 8: 37-43.
19. Bailey PH. Death stories: acute exacerbations of chronic obstructive pulmonary disease. Qualitative Health Res 2001; 11: 322-338.
20. Steinhauser KE, Clipp EC, McNeilly M, Christakis NA, McIntyre LM, Tulsky JA. In search of a good death: observations of patients, families, and providers. Ann Int Med 2000; 132: 825-832.
21. Cherniack NS, Altose MD. Mechanisms of dyspnea. Clin Chest Med 1987; 8: 207-214.
22. Tobin MJ. Dyspnea: pathophysiologic basis, clinical presentation, and management. Arch Intern Med 1990; 150: 1604-1613.
23. Manning HL, Schwartzstein RM. Mechanisms of dyspnea. In: Mahler D, ed. Dyspnea. New York: Marcel Dekker, 1998: 63-95.
24. Simon PM, Schwartzstein RM, Weiss JW, Fencl V, Teghtsoonian M, Weinberger SE. Distinguishable types of dyspnea in patients with shortness of breath. Am Rev Respir Dis 1990; 142: 1009-1014.
25. O’Donnell DE. Exertional breathlessness in chronic respiratory disease. In: Mahler D, ed. Dyspnea. New York: Marcel Dekker, 1998: 97-147.
26. Dudgeon D, Lertzman M. Dyspnea in the advanced cancer patient. J Pain Symptom Manage 1998; 16: 212-219.
27. Gift AG, Plaut SM, Jacox A. Psychologic and physiologic factors related to dyspnea in subjects with chronic obstructive pulmonary disease. Heart Lung 1986; 15: 595-601.
28. Howell J. Behavioral breathlessness. In: McMaster University, ed. “Breathlessness” The Campbell Symposium May 16-19, 1991. Boehringer Ingelheim, 1992: 149-155.
29. Kellner R, Samet J, Pathak D. Dyspnea, anxiety, and depression in chronic respiratory impairment. Gen Hosp Psychiatry 1992; 14: 20-28.
30. Dudgeon DJ, Lertzman M, Askew GR. Physiological changes and clinical correlations of dyspnea in cancer outpatients. J Pain Symptom Manage 2001; 21: 373-379.
31. Bruera E, Schmitz B, Pither J, Neumann CM, Hanson J. The frequency and correlates of dypsnea in patients with advanced cancer. J Pain Symptom Manage 2000; 19: 357-362.
32. Debigare R, Cote CH, Maltais F. Peripheral muscle wasting in chronic obstructive pulmonary disease: clinical relevance and mechanisms. Am J Respir Crit Care Med 2001; 164: 1712-1717.
33. MacDonald SM, Hagen NA, Bruera E. Proximal muscle weakness in a patient with hepatocellular carcinoma. J Pain Symptom Manage 1994; 9: 346-350.
34. Mancini DM, Walter G, Reichek N, Lenkinski R, McCully KK, Mullen JL, et al. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation 1992; 85: 1364-1373.
35. Ansari A. Syndromes of cardiac cachexia and the cachectic heart: current perspective. Prog Cardiovasc Dis 1987; 30: 45-60.
36. Minotti JR, Christoph I, Oka R, Weiner MW, Wells L, Massie BM. Impaired skeletal muscle function in patients with congestive heart failure. Relationship to systemic exercise performance. J Clin Invest 1991; 88: 2077-2082.
37. Rochester DF, Braun NM. Determinants of maximal inspiratory pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis 1985; 132: 42-47.
38. Dudgeon DJ, O’Donnell DE, Day A, Webb KA, McBride I, Dillon K. Mechanisms of exertional dyspnea in patients with cancer: a case-matched control study [abstr]. J Palliat Care 2002; 18: 207.
39. Hamilton AL, Killian KJ, Summers E, Jones NL. Muscle strength, symptom intensity, and exercise capacity in patients with cardiorespiratory disorders. Am J Respir Crit Care Med 1995; 152: 2021-2031.
40. Lindsay DC, Lovegrove CA, Dunn MJ, Bennett JG, Pepper JR, Yacoub MH, et al. Histological abnormalities of muscle from limb, thorax and diaphragm in chronic heart failure. Eur Heart J 1996; 17: 1239-1250.
41. Drexler H, Riede U, Munzel T, Konig H, Funke E, Just H. Alterations of skeletal muscle in chronic heart failure. Circulation 1992; 85: 1751-1759.
42. Lewis MI, Belman MJ. Nutrition and the respiratory muscles. Clin Chest Med 1988; 9: 337-347.
43. Burns BH, Howell JBL. Disproportionately severe breathlessness in chronic bronchitis. Q J Med 1969; 38: 277-294.
44. Reid MB, Lannergren J, Westerblad H. Respiratory and limb muscle weakness induced by tumor necrosis factor-a: involvement of muscle myofilaments. Am J Respir Crit Care Med 2002; 166: 479-484.
45. Rochester DF, Arora NS. Respiratory muscle failure. Med Clin North Am 1983; 67: 573-597.
46. Decramer M, Lacquet IM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994; 150: 11-16.
47. Engelen MP, Schols AM, Baken WC, Wesseling GJ, Wouters EF. Nutritional depletion in relation to respiratory and peripheral skeletal muscle function in out-patients with COPD. Eur Respir J 1994; 7: 1793-1797.
48. Whittaker JS, Ryan CF, Buckley PA, Road JD. The effects of refeeding on peripheral and respiratory muscle function in malnourished chronic obstructive pulmonary disease patients. Am Rev Respir Dis 1990; 142: 283-288.
49. O’Donnell DE, McGuire M, Samis L, Webb KA. The impact of exercise reconditioning on breathlessness in severe chronic airflow limitation. Am J Respir Crit Care Med 1995; 152: 2005-2013.
50. Schols AM, Soeters PB, Mostert R, Pluymers RJ, Wouters EF. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit Care Med 1995; 152: 1268-1274.
51. Kane RD, Hawkins HK, Miller JA, Noce PS. Microscopic pulmonary tumor emboli associated with dyspnea. Cancer 1975; 36: 1473-1482.
52. Chad DA, Recht LD. Neurological paraneoplastic syndromes. Cancer Invest 1988; 6: 67-82.
53. Laroche CM, Mier AK, Spiro SG, Newsom-Davis J, Moxham J, Green M. Respiratory muscle weakness in the Lambert-Eaton myasthenic syndrome. Thorax 1989; 44: 913-918.
54. Manning HL, Schwartzstein RM. Pathophysiology of dyspnea. N Engl J Med 1995; 333: 1547-1553.
55. Silvestri GA, Mahler DA. Evaluation of dyspnea in the elderly patient. Clin Chest Med 1993; 14: 393-404.
56. Ferrin MS, Tino G. Acute dyspnea. Am Assoc Crit Care Nurses Clin Issues 1997; 8: 398-410.
57. Barach AL. Chronic obstructive lung disease: postural relief of dyspnea. Arch Phys Med Rehabil 1974; 55: 494-504.
58. Sharp JT, Drutz WS, Moisan T, Foster J, Machnach W. Postural relief of dyspnea in severe chronic obstructive pulmonary disease. Am Rev Respir Dis 1980; 122: 201-211.
59. Thoman RL, Stoker GL, Ross JC. The efficacy of pursed-lips breathing in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1966; 93: 100-106.
60. Mueller RE, Petty TL, Filley GF. Ventilation and arterial blood gas changes induced by pursed lip breathing. J Appl Physiol 1970; 28: 784-789.
61. Make B. COPD: management and rehabilitation. Am Family Physician 1991; 43: 1315-1324.
62. Schwartzstein RM, Lahive K, Pope A, Weinberger SE, Weiss JW. Cold facial stimulation reduces breathlessness induced in normal subjects. Am Rev Respir Dis 1987; 136: 58-61.
63. Burgess KR, Whitelaw WA. Effects of nasal cold receptors on pattern of breathing. J Appl Physiol 1988; 64: 371-376.
64. Burgess KR, Whitelaw WA. Reducing ventilatory response to carbon dioxide by breathing cold air. Am Rev Respir Dis 1984; 129: 687-690.
65. Shih F, Chu S. Comparisons of American-Chinese and Taiwanese patients’ perceptions of dyspnea and helpful nursing actions during the intensive care unit transition from cardiac surgery. Heart Lung 1999; 28: 41-54.
66. Jobst K, Chen JH, McPherson J. Controlled trial of acupuncture for disabling breathlessness. Lancet 1986; ii: 1416-1418.
67. Maa SH, Gauthier D, Turner M. Acupressure as an adjunct to a pulmonary rehabilitation program. J Cardiopulmonary Rehabil 1997; 17: 268-276.
68. Filshie J, Penn K, Ashley S, Davis CL. Acupuncture for the relief of cancerrelated breathlessness. Palliat Med 1996; 10: 145-150.
69. Renfroe KL. Effect of progressive relaxation on dyspnea and state anxiety in patients with chronic obstructive pulmonary disease. Heart Lung 1988; 17: 408-413.
70. Rosser RM, Denford J, Heslop A. Breathlessness and psychiatric morbidity in chronic bronchitis and emphysema: a study of psychotherapeutic management. Psychol Med 1983; 13: 93-110.
71. Corner J, Plant H, A’Hern R, Bailey C. Non-pharmacological intervention for breathlessness in lung cancer. Palliat Med 1996; 10: 299-305.
72. Moody LE, Fraser M, Yarandi H. Effects of guided imagery in patients with chronic bronchitis and emphysema. Clin Nurs Res 1993; 2: 478-486.
73. Giasson M, Bouchard L. Effect of therapeutic touch on the well-being of persons with terminal cancer. J Hol Nurs 1998; 16: 383-398.
74. British Thoracic Society Standards of Care Committee. Non-invasive ventilation in acute respiratory failure. Thorax 2002; 57: 192-211.
75. Gross NJ. Pulmonary effects of radiation therapy. Ann Int Med 1977; 86: 81-92.
76. Bruera E, Macmillan K, Pither J, MacDonald RN. Effects of morphine on the dyspnea of terminal cancer patients. J Pain Sympt Manage 1990; 56: 341-344.
77. Bruera E, MacEachern T, Ripamonti C, Hanson J. Subcutaneous morphine for dyspnea in cancer patients. Ann Int Med 1993; 119: 906-907.
78. Cohen MH, Johnston AA, Krasnow SH, Spagnolo SV, Citron ML, Payne M, et al. Continuous intravenous infusion of morphine for severe dyspnea. South Med J 1991; 84: 2: 229-234.
79. Light RW, Muro JR, Sato RI, Stansbury DW, Fischer CE, Brown SE. Effects of oral morphine on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 139: 126-133.
80. Masood AR, Subhan MMF, Reed JW, Thomas SHL. Effects of inhaled nebulized morphine on ventilation and breathlessness during exercise in healthy man. Clin Sci 1995; 88: 447-452.
81. Robin ED, Burke CM. Single-patient randomized clinical trial: opiates for intractable dyspnea. Chest 1986; 90: 888-892.
82. Johnson MA, Woodcock AA, Geddes DM. Dihydrocodeine for breathlessness in “pink puffers.” Brit Med J 1983; 286: 675-677.
83. Woodcock AA, Gross ER, Gellert A, Shah S, Johnson M, Geddes DM. Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. N Engl J Med 1981; 305: 1611-1616.
84. Sackner MA. Effects of hydrocodone bitartrate on breathing pattern of patients with chronic obstructive pulmonary disease and restrictive lung disease. Mt Sinai J Med 1984; 51: 222-226.
85. Timmis AD, Rothman MT, Henderson MA, Geal PW, Chamberlain DA. Haemodynamic effects of intravenous morphine in patients with acute myocardial infarction complicated by severe left ventricular failure. Br Med J 1980; 280: 980-982.
86. Rice KL, Kronenberg RS, Hedemark LL, Niewoehner DE. Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Br J Dis Chest 1987; 81: 287-292.
87. Eiser N, Denman WT, West C, Luce P. Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the “pink puffer” syndrome. Eur Respir J 1991; 4: 926-931.
88. Boyd KJ, Kelly M. Oral morphine as symptomatic treatment of dyspnoea in patients with advanced cancer. Palliat Med 1997; 11: 277-281.
89. Poole PJ, Veale AG, Black PN. The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1877-1880.
90. Jennings AL, Davies A, Higgins JPT, Broadley K. Opioids for the palliation of breathlessness in terminal illness (Cochrane rev). In: The Cochrane Library. 4th issue. Oxford: Update Software, 2001.
91. Woodcock AA, Johnson MA, Geddes DM. Breathlessness, alcohol and opiates. N Engl J Med 1982; 306: 1363-1364.
92. Light RW, Stansbury DW, Webster JS. Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Chest 1996; 109: 975-981.
93. Chua TP, Harrington D, Ponikowski P, Webb-Peploe K, Poole-Wilson PA, Coats AJ. Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 1997; 29: 147-152.
94. Zebraski SE, Kochenash SM, Raffa RB. Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sci 2000; 66: 2221-2231.
95. Beauford W, Saylor TT, Stansbury DW, Avalos K, Light RW. Effects of nebulized morphine sulfate on the exercise tolerance of the ventilatory limited COPD patient. Chest 1993; 104: 175-178.
96. Davis CL, Hodder C, Love S, Shah R, Slevin M, Wedzicha J. Effect of nebulised morphine and morphine 6-glucuronide on exercise endurance in patients with chronic obstructive pulmonary disease. Thorax 1994; 49: 393P.
97. Davis CL, Penn K, A’Hern R, Daniels J, Slevin M. Single dose randomised controlled trial of nebulised morphine in patients with cancer related breathlessness [abstr]. Palliat Med 1996; 10: 64-65.
98. Harris-Eze AO, Sridhar G, Clemens RE, Zintel TA, Gallagher CG, Marciniuk DD. Low-dose nebulized morphine does not improve exercise in interstitial lung disease. Am J Respir Crit Care Med 1995; 152: 1940-1945.
99. Jankelson D, Hosseini K, Mather LE, Seale JP, Young IH. Lack of effect of high doses of inhaled morphine on exercise endurance in chronic obstructive pulmonary disease. Eur Respir J 1997; 10: 2270-2274.
100. Leung R, Hill P, Burdon JGW. Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax 1996; 51: 596-600.
101. Masood AR, Reed JW, Thomas SHL. Lack of effect of inhaled morphine on exercise-induced breathlessness in chronic obstructive pulmonary disease. Thorax 1995; 50: 629-634.
102. Noseda A, Carpiaux JP, Markstein C, Meyvaert A, de Maertelaer V. Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine. Eur Respir J 1997; 10: 1079-1083.
103. Young IH, Daviskas E, Keena VA. Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax 1989; 44: 387-390.
104. Wilson RH, Hoseth W, Dempsey ME. Respiratory Acidosis_: I. Effects of decreasing respiratory minute volume in patients with severe chronic pulmonary emphysema, with specific reference to oxygen, morphine and barbitures. Am J Med 1954; 17: 464-470.
105. Ajemian I. Palliative management of dyspnea. J Palliat Care 1991; 73: 44-45.
106. Mazzocato C, Buclin T, Rapin CH. The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: a randomized double-blind controlled trial. Ann Oncol 1999; 10: 1511-1514.
107. Dudgeon DJ, Rosenthal S. Management of dyspnea and cough in patients with cancer. Hematol/Oncol Clin North Am 1996; 10: 157-171.
108. Dudgeon D. Dyspnea-Ethical concerns. Ethics in palliative care-Part II. J Palliat Care 1994; 10: 48-51.
109. Twycross R. Morphine and dyspnoea. In: Pain Relief in Advanced Cancer. New York: Churchill Livingstone, 1994: 383-399.
110. O’Neill PA, Morton PB, Stark RD. Chlorpromazine-a specific effect on breathlessness? Br J Clin Pharmacol 1985; 19: 793-797.
111. Woodcock AA, Gross ER, Geddes DM. Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. Br Med J 1981; 283: 343-346.
112. McIver B, Walsh D, Nelson K. The use of chlorpromazine for symptom control in dying cancer patients. J Pain Symptom Manage 1994; 9: 341-345.
113. Ventafridda V, Spoldi E, De Conno F. Control of dyspnea in advanced cancer patients. Chest 1990; 98: 1544-1545.
114. Sen D, Jones G, Leggat PO. The response of the breathless patient treated with diazepam. Br J Clin Pract 1983; 37: 232-233.
115. Mitchell-Heggs P, Murphy K, Minty K, Guz A, Patterson SC, Minty PSB, et al. Diazepam in the treatment of dyspnoea in the “pink puffer” syndrome. Q J Med 1980; XLIX: 9-20.
116. Greene JG, Pucino F, Carlson JD, Storsved M, Strommen GL. Effects of alprazolam on respiratory drive, anxiety, and dyspnea in chronic airflow obstruction: a case study. Pharmacotherapy 1989; 9: 34-38.
117. Man GCW, Hsu K, Sproule BJ. Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest 1986; 90: 832-836.
118. Eimer M, Cable T, Gal P, Rothenberger LA, McCue JD. Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. J Fam Pract 1985; 21: 359-362.
119. Argyropoulou P, Patakas D, Koukou A, Vasiliadis P, Georgopoulos D. Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. Respiration 1993; 60: 216-220.
120. O’Neill PA, Stark RD, Morton PB. Do prostaglandins have a role in breathlessness? Am Rev Respir Dis 1985; 132: 22-24.
121. O’Neill PA, Stretton TB, Stark RD, Ellis SH. The Effect of indomethacin on breathlessness in patients with diffuse parenchymal disease of the lung. Br J Dis Chest 1986; 80: 72-79.
122. Schiffman GL, Stansbury DW, Fischer CE, Sato RI, Light RW, Brown SE. Indomethacin and perception of dyspnea in chronic airflow limitation. Am Rev Respir Dis 1988; 137: 1094-1098.
123. Winning AJ, Hamilton RD, Shea SA, Knott C, Guz A. The effect of airway anaesthesia on the control of breathing and the sensation of breathlessness in man. Clin Sci 1985; 68: 215-225.
124. Winning AJ, Hamilton RD, Guz A. Ventilation and breathlessness on maximal exercise in patients with interstitial lung disease after local anaesthetic aerosol inhalation. Clin Sci 1988; 74: 275-281.
125. Wilcock A, Corcoran R, Tattersfield AE. Safety and efficacy of nebulized lignocaine in patients with cancer and breathlessness. Palliat Med 1994; 8: 35-38.
126. Giron AE, Stansbury DW, Fischer CE, Light RW. Lack of effect of dextromethorphan on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 1991; 4: 532-535.
127. Shepard KV. Dyspnea in cancer patients. Palliat Care Lett 1990; 2(6 Insert 1): 1.
128. Cowcher K, Hanks GW. Long-term management of respiratory symptoms in advanced cancer. J Pain Sympt Manage 1990; 5: 320-330.
129. Kaplan JD. Acute respiratory failure. In: Woodley M, Whelan A, eds. Manual of Medical Therapeutics: The Washington Manual. 27th ed. Boston: Little, Brown and Company, 1992: 179-195.
130. Tarpy SP, Celli BR. Long-term oxygen therapy. N Engl J Med 1995; 333: 710-714.
131. Bruera E, de Stoutz N, Velasco-Leiva A, Schoeller T, Hanson J. Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. Lancet 1993; 342: 13-14.
132. Bruera E, Schoeller T, MacEachern T. Symptomatic benefit of supplemental oxygen in hypoxemic patients with terminal cancer: the use of the N of 1 randomized controlled trial. J Pain Sympt Manage 1992; 7: 365-368.
133. Woodcock AA, Gross ER, Geddes DM. Oxygen relieves breathlessness in “pink puffers.” Lancet 1981; 1: 907-909.
134. Booth S, Kelly M, Cox NP, Adams L, Guz A. Does oxygen help dyspnea in patients with cancer?. Am J Respir Crit Care Med 1996; 153: 1515-1518.
135. American Thoracic Society. Dyspnea. Mechanisms, assessment, and management: a consensus statement. Am J Respir Crit Care Med 1999; 159: 321-340.
136. Prendergast TJ, Luce JM. Increasing incidence of withholding and withdrawal of life support from the critically ill. Am J Respir Crit Care Med 1997; 155: 15-20.
137. Brody H, Campbell ML, Faber-Langendoen K, Ogle KS. Withdrawing intensive life-sustaining treatment-recommendations for compassionate clinical management. N Engl J Med 1997; 336: 652-657.
138. Von Gunten C, Weissman DE. Fast Facts and Concepts #33: Ventilator Withdrawal Protocol, 2001 January.
139. Von Gunten C, Weissman DE. Fast Facts and Concepts #34: Symptom Control for Ventilator Withdrawal in the Dying Patient, 2001 February.
140. Kingston General Hospital. Guidelines for the Process of Withdrawal of Life Support in the Intensive Care Unit, 2000.
141. Levenson JW, McCarthy EP, Lynn J, Davis RB, Phillips RS. The last six months of life for patients with congestive heart failure. J Am Geriatr Soc 2000; 48: S101-S109.
142. Claessens MT, Lynn J, Zhong Z, Desbiens NA, Phillips RS, Wu AW, et al. Dying with lung cancer or chronic obstructive pulmonary disease: insights from SUPPORT. J Am Geriatr Soc 2000; 48: S146-S153.
143. Lunney JR, Lynn J, Foley DJ, Lipson S, Guralnik JM. Patterns of functional decline at the end of life. JAMA 2003; 289: 2387-2392.
144. Teno JM, Weitzen S, Fennell ML, Mor V. Dying trajectory in the last year of life: does cancer trajectory fit other diseases? J Palliative Med 2001; 4: 457-464.
145. Lynn J, Schall MW, Milne C, Nolan KM, Kabcenell A. Quality improvements in end of life care: insights from two collaboratives. Joint Comm J Qual Improv 2000; 26: 254-267.
146. Curtis JR, Wenrich MD, Carline JD, Shannon SE, Ambrozy DM, Ramsey PG. Patients’ perspectives on physician skill in end-of-life care. Differences between patients with COPD, cancer, and AIDS. Chest 2002; 122: 356-362.
147. Curtis JR. Communicating with patients and their families about advance care planning and end-of-life care. Respir Care 2000; 45: 1385-1394.
148. Heffner JE, Fahy B, Hilling L, Barbieri C. Attitudes regarding advance directives among patients in pulmonary rehabilitation. Am J Respir Crit Care Med 1996; 154: 1735-1740.
149. Somogyi-Zalud E, Zhong Z, Lynn J, Dawson NV, Hamel MB, Desbiens NA. Dying with acute respiratory failure or multiple organ system failure with sepsis. J Am Geriatr Soc 2000; 48: S140-S145.